ANEB — Anebulo Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $47.25m
- $32.25m
- 34
- 20
- 28
- 16
Annual income statement for Anebulo Pharmaceuticals, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 0.173 | 3.61 | 6.83 | 11.8 | 8.31 |
| Operating Profit | -0.173 | -3.61 | -6.83 | -11.8 | -8.31 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -0.175 | -30.3 | -6.83 | -11.7 | -8.2 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -0.175 | -30.3 | -6.83 | -11.7 | -8.2 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.175 | -30.3 | -6.83 | -11.7 | -8.2 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.175 | -38.5 | -6.83 | -11.7 | -8.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.008 | -1.65 | -0.292 | -0.468 | -0.318 |
| Dividends per Share |